Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Mwanasha Merrill, MD
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07588698CT.gov Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07528352CT.gov External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL | — | Recruiting | — | — | — |
NCT07365306CT.gov Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | Recruiting | — | — | — |
NCT07097363CT.gov Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT07126236CT.gov Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma | — | Recruiting | — | — | — |
NCT06905509CT.gov Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT06652139CT.gov Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive | — | Not Yet Recruiting | — | — | — |
NCT06652165CT.gov Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL | — | Not Yet Recruiting | — | — | — |
NCT06458439CT.gov Epcoritamab-CAR T Cells for Large B-cell Lymphomas | — | Recruiting | — | — | — |
NCT06508658CT.gov A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
Show 45 more trialsShow fewer
NCT06238648CT.gov Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | — | Recruiting | — | — | — |
NCT06287398CT.gov Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | — | Recruiting | — | — | — |
NCT05852717CT.gov Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT05863845CT.gov Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | — | Unknown | — | — | — |
NCT05228249CT.gov Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT05660967CT.gov Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05578976CT.gov A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | — | Active Not Recruiting | — | — | — |
NCT07226752CT.gov A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China | — | Active Not Recruiting | — | — | — |
NCT05451810CT.gov A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05466318CT.gov ChiCGB vs BEAM in High-risk or R/R Lymphomas | — | Unknown | — | — | — |
NCT05518383CT.gov B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | — | Recruiting | — | — | — |
NCT04628494CT.gov A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | — | Active Not Recruiting | — | — | — |
NCT04663347CT.gov Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | — | Active Not Recruiting | — | — | — |
NCT04542824CT.gov Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | — | Active Not Recruiting | — | — | — |
NCT04358458CT.gov First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | — | Terminated | — | — | — |
NCT03736616CT.gov Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | — | Unknown | — | — | — |
NCT03625037CT.gov First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03356054CT.gov Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse | — | Recruiting | — | — | — |
NCT03072771CT.gov Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | — | Completed | — | — | — |
NCT02483000CT.gov Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies | — | Terminated | — | — | — |
NCT03383406CT.gov A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma | — | Unknown | — | — | — |
NCT02481310CT.gov Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT02570542CT.gov Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | — | Active Not Recruiting | — | — | — |
NCT02393157CT.gov Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | — | Recruiting | — | — | — |
NCT01769911CT.gov Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | — | Withdrawn | — | — | — |
NCT02329080CT.gov New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | — | Completed | — | — | — |
NCT02374424CT.gov Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients | — | Terminated | — | — | — |
NCT01859819CT.gov Treatment for Advanced B-Cell Lymphoma | — | Completed | — | — | — |
NCT01653067CT.gov STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma | — | Unknown | — | — | — |
NCT01453205CT.gov A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | — | Completed | — | — | — |
NCT01481272CT.gov Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients | — | Completed | — | — | — |
NCT02340936CT.gov Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma | — | Completed | — | — | — |
NCT01278602CT.gov R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma | — | Unknown | — | — | — |
NCT00992446CT.gov Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00945724CT.gov Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis | — | Completed | — | — | — |
NCT00823719CT.gov Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | — | Completed | — | — | — |
NCT00591630CT.gov Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | — | Completed | — | — | — |
NCT00689169CT.gov Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma | — | Completed | — | — | — |
NCT00499018CT.gov Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | — | Unknown | — | — | — |
NCT01502982CT.gov Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04) | — | Completed | — | — | — |
NCT00057811CT.gov Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | — | Completed | — | — | — |
NCT00137995CT.gov R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | — | Completed | — | — | — |
NCT00556127CT.gov Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | — | Completed | — | — | — |
NCT00187070CT.gov Large Cell Lymphoma Pilot Study III | — | Completed | — | — | — |
NCT05733650CT.gov Expanded Access Program for Epcoritamab | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytarabine (this asset) | Mwanasha Merrill, MD | Approved | BB · 69 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | A |
| Melphalan | Ruijin Hospital | P4 | BBB |
| Axicabtagene Ciloleucel | Ruijin Hospital | P4 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Nivestim | Ruijin Hospital | P3 | BBB |
| Rituximab | Beth Israel Deaconess Medical Center | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for Cytarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cytarabine in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cytarabine-diffuse-large-b-cell-lymphoma-38126
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →